Hengrui H1 Revenue Falls 1.94% to RMB15.456 Billion, Net Profit Up 0.34%, Plans RMB1-2 Billion Buyback
Hengrui Pharmaceuticals reported on August 19 a 1.94% year-on-year decline in first-half operating revenue to RMB15.456 billion, while net profit attributable to shareholders rose 0.34% to RMB4.465 billion, with basic earnings per share at RMB0.68. The company also proposed a share repurchase of between RMB1 billion and RMB2 billion for its employee stock ownership plan, at a maximum repurchase price of RMB81.78 per share.
Hengrui Pharmaceuticals disclosed its 2026 semi-annual report on August 19. During the reporting period, the company recorded operating revenue of RMB15.456 billion, a year-on-year decrease of 1.94%; net profit attributable to shareholders of the listed company reached RMB4.465 billion, an increase of 0.34% year-on-year; and basic earnings per share stood at RMB0.68.
In a separate announcement on the same day, the company proposed to repurchase its A shares for an amount between RMB1 billion and RMB2 billion, to be used for an employee stock ownership plan, with a maximum repurchase price of RMB81.78 per share.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is mixed for Pharmaceuticals, with intensity 40/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.